CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics
CNSP Price/Volume Stats
| Current price | $1.17 | 52-week high | $6.90 |
| Prev. close | $1.22 | 52-week low | $0.61 |
| Day low | $1.17 | Volume | 32,100 |
| Day high | $1.28 | Avg. volume | 1,348,282 |
| 50-day MA | $1.82 | Dividend yield | N/A |
| 200-day MA | $1.90 | Market Cap | 4.92M |
CNSP Stock Price Chart Interactive Chart >
CNS PHARMACEUTICALS, INC. (CNSP) Company Bio
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.
Latest CNSP News From Around the Web
Below are the latest news stories about CNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNSP as an investment opportunity.
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that 200 of the expected 243 patients have now been enrolled in the Company's ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. |
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceCNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York, NY on Wednesday, September 13, 2023 at 10:30 AM ET. |
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line TherapyCNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a |
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming MilestonesCNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterates upcoming milestones. |
CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech ConferenceCNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will participate in a fireside chat at Benzinga's Virtual Biotech Conference on Thursday, August 3, 2023 at 11:35 AM ET. |
CNSP Price Returns
| 1-mo | -33.14% |
| 3-mo | -50.21% |
| 6-mo | 7.34% |
| 1-year | -79.67% |
| 3-year | -97.83% |
| 5-year | N/A |
| YTD | -51.25% |
| 2022 | -88.61% |
| 2021 | -60.54% |
| 2020 | -54.94% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...